Viyash Scientific
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Viyash Scientific's recent management commentary highlights a strategic pivot towards high-value therapeutic molecules and a focus on the companion animal health market, which is expected to drive revenue growth. The successful integration of its manufacturing and R&D platforms positions the company to leverage its USFDA-approved sites effectively, enhancing its competitive position in the expanding veterinary healthcare sector. Vista's financial outlook anticipates a 15% revenue growth rate over the next five years, supported by a robust product pipeline and disciplined capital allocation following a deleveraged balance sheet. However, potential headwinds include regulatory complexities in the US market and raw material price volatility, which could impact margins. The industry context remains favorable, with improving pricing power and a projected CAGR of 7.37% for the Pharma APIs and CRAMS sector, further supporting Viyash's growth trajectory. Over the next 12-24 months, key opportunities lie in expanding geographic reach and product offerings, while watchpoints include managing integration risks and navigating supply chain challenges
Why We Like This Stock
- Management's focus on high-value therapeutic molecules and the companion animal health segment is expected to drive significant revenue growth
- The successful integration of manufacturing and R&D capabilities enhances operational efficiency and market competitiveness
- The industry is experiencing favorable conditions, with improving pricing power and a strong growth outlook for Indian CDMOs
Things To Watch Out For
- Regulatory complexities in the US companion animal market pose risks to growth and compliance
- Volatility in raw material prices could impact profit margins in the short term
- Integration risks associated with recent acquisitions may affect operational stability and execution
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 1,370 | 1,551 | 3,420 | 3,719 | 4,050 |
| Profit Before Tax (Cr.) | -43 | 43 | 393 | 469 | 499 |
| PBT Margin | -3.2% | 2.8% | 11.5% | 12.6% | 12.3% |
| Net Profit (Cr.) | -60 | -47 | 314 | 382 | 346 |
| Earnings Per Share | -1.5 | -1.3 | 6.1 | 7.4 | 7.9 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Anand Rathi | ▲ Buy | 310 | 30-Jun-2026 |
| Systematix Shares | ▲ Buy | 264 | 07-May-2026 |
Company Overview
Show Company Profile
Viyash Scientific Limited operates as a veterinary pharmaceutical Company in India, the United States, Spain, and internationally. The company provides active pharmaceutical ingredients, finished dosage formulations, analytical services, and VET formulation services for cattle and poultry. The company was formerly known as Sequent Scientific Limited and changed its name to Viyash Scientific Limited in January 2026. The company was incorporated in 1985 and is headquartered in Hyderabad, India. Viyash Scientific Limited operates as a subsidiary of CA Harbor Investments.